Truist Financial Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price objective boosted by Truist Financial from $18.00 to $23.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

Other research analysts have also issued reports about the company. Needham & Company LLC upped their target price on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Leerink Partners boosted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research note on Monday, March 16th. BTIG Research reiterated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, Evercore set a $24.00 price target on Hims & Hers Health in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.90.

Hims & Hers Health Trading Down 1.2%

HIMS opened at $23.71 on Friday. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of -263.46, a PEG ratio of 46.59 and a beta of 2.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The stock has a fifty day moving average price of $24.04 and a 200-day moving average price of $28.10.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The company’s revenue was up 3.8% on a year-over-year basis. As a group, equities research analysts anticipate that Hims & Hers Health will post 0.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 9,463 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the transaction, the insider owned 299,368 shares in the company, valued at approximately $8,981,040. This represents a 3.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,950 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $23.64, for a total value of $187,938.00. Following the transaction, the chief financial officer owned 262,954 shares in the company, valued at $6,216,232.56. This represents a 2.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 212,807 shares of company stock worth $5,473,644 over the last ninety days. 11.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Bogart Wealth LLC lifted its position in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Finally, Greenline Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched generic semaglutide in Canada, giving it first-time international access to the fast-growing GLP-1 market and potentially boosting future sales. Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
• Positive Sentiment: The company is expanding its personalized care platform with labs, hormone programs, and broader global ambitions, which suggests a larger long-term addressable market. Hims & Hers Deepens Personalized Care Through Platform Expansion
• Positive Sentiment: Analyst coverage turned slightly more constructive after Truist raised its price target to $23 from $18, even though the rating remained Hold. Truist Raises Hims & Hers Price Target
• Neutral Sentiment: Additional coverage noted the Canada GLP-1 launch and broader platform expansion, reinforcing investor attention on growth initiatives rather than new financial results. Reuters Canada semaglutide article
• Negative Sentiment: Some commentary remains cautious after the recent earnings miss and sharp prior pullback, reminding investors that execution risk and valuation concerns are still in focus. MarketBeat earnings miss analysis

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.